Keyur Mehta

13.7k total citations · 1 hit paper
32 papers, 4.3k citations indexed

About

Keyur Mehta is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Keyur Mehta has authored 32 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 23 papers in Cancer Research and 10 papers in Pathology and Forensic Medicine. Recurrent topics in Keyur Mehta's work include Breast Cancer Treatment Studies (22 papers), HER2/EGFR in Cancer Research (16 papers) and Cancer Treatment and Pharmacology (12 papers). Keyur Mehta is often cited by papers focused on Breast Cancer Treatment Studies (22 papers), HER2/EGFR in Cancer Research (16 papers) and Cancer Treatment and Pharmacology (12 papers). Keyur Mehta collaborates with scholars based in Germany, Switzerland and United States. Keyur Mehta's co-authors include Sibylle Loibl, Gϋnter von Minckwitz, Bernd Gerber, Jens Huober, Michael Untch, Carsten Denkert, Jens‐Uwe Blohmer, Holger Eidtmann, Peter A. Fasching and Christian Jackisch and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Keyur Mehta

32 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

2012 1.8k citations Gϋnter von Minckwitz, Michael Untch et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Keyur Mehta

Since Specialization

Citations

This map shows the geographic impact of Keyur Mehta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keyur Mehta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keyur Mehta more than expected).

Fields of papers citing papers by Keyur Mehta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keyur Mehta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keyur Mehta. The network helps show where Keyur Mehta may publish in the future.

Co-authorship network of co-authors of Keyur Mehta

This figure shows the co-authorship network connecting the top 25 collaborators of Keyur Mehta. A scholar is included among the top collaborators of Keyur Mehta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keyur Mehta. Keyur Mehta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy 2023 ·npj Breast Cancer ·Jens Huober, Marion van Mackelenbergh, Andreas Schneeweiß, Fenja Seither, Jens‐Uwe Blohmer, Carsten Denkert, Hans Tesch, Claus Hanusch, Christoph Salat, Kerstin Rhiem, Christine Solbach, Peter A. Fasching, Christian Jackisch, Mattea Reinisch, Bianca Lederer, Keyur Mehta, Theresa Link, Valentina Nekljudova, Sibylle Loibl, Michael Untch	20
2	Fatal events during clinical trials: an evaluation of deaths during breast cancer studies 2019 ·Breast Cancer ·Jenny Furlanetto, Gϋnter von Minckwitz, Bianca Lederer, Volker Möbus, Andreas Schneeweiß, Jens Huober, Peter A. Fasching, Bernd Gerber, Ingo Bauerfeind, Ulrike Nitz, Hans‐Joachim Lück, Claus Hanusch, Christoph Thomssen, Michael Untch, Valentina Nekljudova, Keyur Mehta, Sibylle Loibl	1
3	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer 2016 ·Clinical Cancer Research ·Sibylle Loibl, Silvia Darb‐Esfahani, Jens Huober, Alexander C. Klimowicz, Jenny Furlanetto, Bianca Lederer, Arndt Hartmann, Holger Eidtmann, Berit M. Pfitzner, Peter A. Fasching, Katharina Tiemann, Christian Jackisch, Keyur Mehta, Gϋnter von Minckwitz, Michael Untch, Carsten Denkert	34
4	Risk assessment after neoadjuvant chemotherapy in luminal breast cancer: A prospectively planned validation of gene expression based and clinical prognostic scores in 428 residual tumor samples from two neoadjuvant clinical trials. 2016 ·Journal of Clinical Oncology ·Carsten Denkert, Karsten E. Weber, Kristin Krappmann, Jens Huober, Frederik Marmé, Christian Schem, Knut Engels, Berit M. Pfitzner, Sherko Kümmel, Jenny Furlanetto, Arndt Hartmann, Silvia Darb‐Esfahani, Volkmar Mueller, Annette Staebler, Keyur Mehta, Gϋnter von Minckwitz, Ralf Kronenwett, Sibylle Loibl	1
5	Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials 2015 ·Breast Cancer Research and Treatment ·Sibylle Loibl, Christian Jackisch, Bianca Lederer, Michael Untch, Stefan Paepke, Sherko Kümmel, Andreas Schneeweiß, Jens Huober, J. Hilfrich, Claus Hanusch, Bernd Gerber, Holger Eidtmann, Carsten Denkert, Serban Dan Costa, Jens‐Uwe Blohmer, Valentina Nekljudova, Keyur Mehta, Gϋnter von Minckwitz	77
6	Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study 2014 ·Clinical Cancer Research ·Frederick Klauschen, Stephan Wienert, Wolfgang Schmitt, Sibylle Loibl, Bernd Gerber, Jens‐Uwe Blohmer, Jens Huober, Thomas Rüdiger, E Erbstösser, Keyur Mehta, Bianca Lederer, Manfred Dietel, Carsten Denkert, Gϋnter von Minckwitz	78
7	Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes 2014 ·BMC Cancer ·Silvia Darb‐Esfahani, Gϋnter von Minckwitz, Carsten Denkert, Beyhan Ataseven, B. Högel, Keyur Mehta, (unknown), Thomas Rüdiger, Berit M. Pfitzner, K. Kittel, (unknown), Klaus Baumann, Roland Moll, Manfred Dietel, Holger Eidtmann, Christoph Thomssen, Sibylle Loibl	67
8	Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA* 2014 ·Breast Care ·Sibylle Loibl, (unknown), Bettina Conrad, Nadia Harbeck, (unknown), Mathias Warm, Kathrin Schwedler, Bernd Gerber, Iris Schrader, Holger Eidtmann, Keyur Mehta, Uwe Fuhr, Gϋnter von Minckwitz	10
9	Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy. 2014 ·Journal of Clinical Oncology ·Carsten Denkert, Gϋnter von Minckwitz, Jan C. Brase, Silvia Darb‐Esfahani, Stephan Gade, Ralf Kronenwett, Christoph Salat, Sherene Loi, Christian Schem, Christos Sotiriou, Keyur Mehta, Peter Klare, (unknown), Jens‐Uwe Blohmer, Hans Tesch, Sherko Kümmel, Kristin Krappmann, Manfred Dietel, Michael Untch, Sibylle Loibl	7
10	Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer 2014 ·Breast Cancer Research and Treatment ·Hans‐Joachim Lück, Kristina Lübbe, Mattea Reinisch, Nicolaì Maass, Gabriele Feisel-Schwickardi, Oliver Tomé, Wolfgang Janni, Mustafa Aydoğdu, Tanja Neunhöffer, Angelika Ober, Bahriye Aktas, Tjoung‐Won Park‐Simon, Claudia Schumacher, Heinz‐Gert Höffkes, Thomas Illmer, (unknown), Keyur Mehta, Gϋnter von Minckwitz, Valentina Nekljudova, Sibylle Loibl	19
11	Response-Guided Neoadjuvant Chemotherapy for Breast Cancer 2013 ·Journal of Clinical Oncology ·Gϋnter von Minckwitz, Jens‐Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann, W. Eiermann, Bernd Gerber, Claus Hanusch, J. Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Sherko Kümmel, Stefan Paepke, Andreas Schneeweiß, Michael Untch, Dirk M. Zahm, Keyur Mehta, Sibylle Loibl	265
12	HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer 2013 ·Breast Cancer Research ·Carsten Denkert, Jens Huober, Sibylle Loibl, Judith Prinzler, Ralf Kronenwett, Silvia Darb‐Esfahani, Jan C. Brase, Christine Solbach, Keyur Mehta, Peter A. Fasching, Bruno V. Sinn, Knut Engels, Mattea Reinisch, Martin‐Leo Hansmann, Hans Tesch, Gϋnter von Minckwitz, Michael Untch	49
13	Abstract 4699: Responsecharacteristics and overall survival of 781 patients with triple-negativebreast cancer - a meta-analysis on 7 German neoadjuvant studies. 2013 ·Cancer Research ·Gϋnter von Minckwitz, (unknown), Sibylle Loibl, Jens‐Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann, Bernd Gerber, Claus Hanusch, Joern Hilfrich, Jens Huober, Andreas Schneeweiß, Stefan Paepke, Keyur Mehta, Michael Untch, Christian Jackisch	4
14	Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer 2012 ·PLoS ONE ·Antonia Wenners, Keyur Mehta, Sibylle Loibl, Hye‐Rim Park, (unknown), Norbert Arnold, (unknown), Jörg Weimer, Beyhan Ataseven, Silvia Darb‐Esfahani, Christian Schem, Christoph Mundhenke, F Khandan, Christoph Thomssen, W. Jonat, (unknown), (unknown), Carsten Denkert, M. Bauer	44
15	Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy 2011 ·Breast Care ·Xinrong Guo, Sibylle Loibl, Michael Untch, Volker Möbus, Kathrin Schwedler, Peter A. Fasching, Jana Barinoff, Frank Holms, Christoph Thomssen, Dirk M. Zahm, R. Kreienberg, Maik Hauschild, Holger Eidtmann, (unknown), Keyur Mehta, Gϋnter von Minckwitz, (unknown)	11
16	Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups 2011 ·Journal of Clinical Oncology ·Michael Untch, Peter A. Fasching, Gottfried E. Konecny, Stephan Hasmüller, Annette Lebeau, R. Kreienberg, Oumar Camara, Volkmar Müller, Andreas du Bois, Thorsten Kühn, Elmar Stickeler, Nadia Harbeck, C. Höß, S. Kahlert, Thomas Beck, W. Fett, Keyur Mehta, Gϋnter von Minckwitz, Sibylle Loibl	370
17	Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy 2011 ·Breast Cancer Research and Treatment ·Sibylle Loibl, Berit Müller, Gϋnter von Minckwitz, Michael Schwabe, Marc Roller, Silvia Darb‐Esfahani, Beyhan Ataseven, Andreas du Bois, (unknown), Bernd Gerber, (unknown), (unknown), Keyur Mehta, Carsten Denkert	166
18	Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study 2010 ·Breast Cancer Research and Treatment ·Jens Huober, (unknown), Carsten Denkert, Hans Tesch, Erich Weiß, Dirk M. Zahm, Antje Belau, F Khandan, Maik Hauschild, Christoph Thomssen, B. Högel, Silvia Darb‐Esfahani, Keyur Mehta, Sibylle Loibl	220
19	Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study 2010 ·Journal of Clinical Oncology ·Gϋnter von Minckwitz, Mahdi Rezai, Sibylle Loibl, Peter A. Fasching, Jens Huober, Hans Tesch, Ingo Bauerfeind, J. Hilfrich, Holger Eidtmann, Bernd Gerber, Claus Hanusch, Thorsten Kühn, Andreas du Bois, Jens‐Uwe Blohmer, Christoph Thomssen, Serban Dan Costa, Christian Jackisch, Manfred Kaufmann, Keyur Mehta, Michael Untch	155
20	Darbepoetin Alfa as Primary Prophylaxis of Anemia in Patients with Breast Cancer Treated Preoperatively with Docetaxel/Doxorubicin/Cyclophosphamide 2006 ·PubMed ·Sibylle Loibl, Manfred Kaufmann, (unknown), Keyur Mehta, Katharina Hofmann, Simone Petrich, Gϋnter von Minckwitz	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact